Healthcare Economist

Jason Shafrin, PhD, sheds light on a study that argues that patients are underrepresented in traditional cost-effectiveness analysis and that a patient-informed societal perspective is needed.

Jason Shafrin, PhD, asserts that patients and payers can justifiably complain about the rising prices of targeted therapies, but manufacturers can rightfully argue that the prices need to be this high to maintain revenues.

Jason Shafrin, PhD, explains the difficulty of measuring pharmaceutical value and notes ways in which ICER and IVI are attempting to address this challenge.